Clinical Trial Update: 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 24 weeks of lixisenatide added to metformin and insulin glargine in type 2 diabetes patients with inadequate glycemic control; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• Lixisenatide (lixisenatide)
• metformin (metformin)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2016-10-11